3 Stocks Underperforming Today In The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 37 points (0.2%) at 17,115 as of Thursday, Sept. 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,639 issues advancing vs. 1,333 declining with 167 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the sector include Universal Health Services ( UHS), down 4.4%, Jazz Pharmaceuticals ( JAZZ), down 3.6%, Tenet Healthcare ( THC), down 3.5%, Biomarin Pharmaceutical ( BMRN), down 2.8% and Novo Nordisk A/S ( NVO), down 2.0%. Top gainers within the sector include WellPoint ( WLP), up 1.6%, Cigna ( CI), up 1.3%, Aetna ( AET), up 0.9%, UnitedHealth Group ( UNH), up 0.9% and Thermo Fisher Scientific ( TMO), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Intuitive Surgical ( ISRG) is one of the companies pushing the Health Care sector lower today. As of noon trading, Intuitive Surgical is down $6.67 (-1.4%) to $467.04 on light volume. Thus far, 95,569 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 471,900 shares. The stock has ranged in price between $466.54-$475.40 after having opened the day at $474.16 as compared to the previous trading day's close of $473.71.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $17.0 billion and is part of the health services industry. Shares are up 23.3% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Intuitive Surgical a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Intuitive Surgical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is down $4.63 (-1.4%) to $339.49 on light volume. Thus far, 269,702 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $339.05-$344.44 after having opened the day at $344.37 as compared to the previous trading day's close of $344.12.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $80.9 billion and is part of the drugs industry. Shares are up 23.1% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Celgene ( CELG) is down $0.78 (-0.8%) to $94.16 on light volume. Thus far, 1.2 million shares of Celgene exchanged hands as compared to its average daily volume of 4.5 million shares. The stock has ranged in price between $94.07-$95.39 after having opened the day at $95.23 as compared to the previous trading day's close of $94.94.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $76.0 billion and is part of the drugs industry. Shares are up 12.4% year-to-date as of the close of trading on Wednesday. Currently there are 17 analysts that rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, robust revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Celgene Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE